Naslov
Our experience with safety and effectiveness of biologics in psoriasis

Autori
Prpić Massari, Larisa ; Kaštelan, Marija ; Brajac, Ines ; Simonić, Edita ; Peternel, Sandra ; Novak, Srđan

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
6th Croatian-Italian Symposium on Psoriasis : Abstract Book / - Rijeka, 2012

Skup
Croatian-Italian Symposium on Psoriasis (6 ; 2012)

Mjesto i datum
Rijeka, Hrvatska, 16.11.2012. - 17.11.2012

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
psoriasis; infliximab; adalimumab; etanercept; ustekinumab

Sažetak
Psoriasis is chronic, immune-mediated skin disease. The treatment of psoriasis requires long-lasting effect. Conventional treatments for psoriasis comprise topical solutions, photo and photochemotherapy, retinoids, methotrexate or cyclosporine. However, sometimes those treatments fail, are contraindicated or are associated with severe adverse events. Therefore novel biologic response modifiers or simply biologic agents are indicated in such cases. They act by targeting the precise elements in immunological cascade. Therefore, they can be classified into three categories: T- cell modulating agents (eg. alefacept and efalizumab), the inhibitors of tumor necrosis factor- alpha (TNF-alpha) (eg. adalimumab, etanercept, infliximab) and the inhibitors of interleukin (IL)-12 and IL-23 (eg. ustekinumab). Herein, we present our four years experience (2008-2012), mostly assess and compare effectiveness and safety of different biologics used in treatment of moderate to severe psoriasis.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA